Poly(ethylene glycol) with Observable Shedding by Gao, Weiwei et al.
Poly(ethylene glycol) with
Observable Shedding
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Gao, Weiwei, Robert Langer, and Omid￿C. Farokhzad. 2010.
“Poly(ethylene Glycol) with Observable Shedding.” Angewandte




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
PEG with Observable Shedding**
Dr. Weiwei Gao,
Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and
Women’s Hospital, Boston, MA 02115 USA
Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge,
MA 02139 USA
Dr. Robert Langer, and
Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge,
MA 02139 USA
Dr. Omid C. Farokhzad
Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and
Women’s Hospital, Boston, MA 02115 USA
Abstract
A novel FRET-bearing poly(ethylene glycol) (PEG) conjugate fluoresces at 520 nm when it is
cleaved off from nanoparticles (NPs). When the NPs were targeted to cancer cell lines, the
reducing redox of the endosomal compartment caused disulfide bond cleavage and shedding of the
PEG layer. The fluorescence emission can be suppressed by N-ethylmaleimide to inhibit disulfide
cleavage and restored by dithiothreitol, a disulfide cleavage reagent, indicating a direct correlation
between fluorescence emission and PEG shedding.
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The surface functionalization of nanoparticle (NP) drug delivery systems with poly(ethylene
glycol) (PEG) has become a preferred coating strategy to increase NP circulation time by
reducing protein opsonization and macrophage uptake.[1, 2] Indeed, several clinically-
approved therapeutics rely on PEG for improved in vivo profiles, including PEG-liposomes
(e.g. Doxil®), PEG-drug conjugates (e.g. Oncaspar®) and polymeric NPs (e.g. Genexol-
PM®).[3] However, it has been reported that the benefit from using PEG to increase
circulation half-time may be compromised by PEG which may cause steric and electrostatic
hindrance to the entry of NPs at target sites.[4] Even after the NPs are endocytosed at these
target sites, the PEG layer can still act as a diffusion barrier to NPs for the efficient release
of their payloads.[5] To overcome this ‘PEG dilemma’, it has been proposed that PEG-
sheddable NPs may be formulated by crosslinking PEG using disulfide bond that is cleaved
in response to the reducing conditions.[6]
Previous research has shown that some NP delivery systems, when equipped with disulfide-
linked sheddable PEG, show cell-responsive dynamics and improved delivery of therapeutic
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molecules. For example, Takae et al. reported poly(aspartamide) based plasmid gene
delivery NPs that showed enhanced gene expression by using cleavable disulfide bonds to
crosslink the stealth PEG layer.[7] In another example, Cerritelli et al. observed faster
cytoplasm release of calcein from NPs formed using PEG-SS-poly(propylene sulfide) co-
polymers when compared with a non-cleavable formulation.[8] However, so far, assays to
evaluate PEG shedding are end-point focused and yield no information of PEG shedding
process during NP-cell interactions. In addition, these functional assays are unique to the
delivery of the specific payloads, and thus may not be generalized across NP systems. In an
effort to rationally design PEG-sheddable NPs for efficient and environment-sensitive
delivery, it would be desirable to develop a method to directly observe PEG-shedding across
various NP systems and conditions.
To achieve this goal, we designed and synthesized a PEG molecule that bears a disulfide-
based fluorescence resonance energy transfer (FRET) pair, containing an Oregon Green-488
(OG-488) as donor and a Dabcyl molecule as quencher (Figure 1). When the disulfide bond
is intact, only minimal fluorescence from OG-488 can be detected due to intramolecular
quenching. However, if the PEG chain is shed due to disulfide cleavage, intramolecular
quenching is abolished and increased fluorescence can be measured.[9] Notably, our design
preserves a reactive amine group in the FRET-bearing PEG molecule, which allows for
conjugation to different NP systems. In this study, we choose to conjugate the FRET-bearing
PEG molecule with poly(lactic-co-glycolic acid) (PLGA) to form PLGA-(FRET)-PEG NPs
as a model polymeric NP platform. Using this NP formulation, we are able to directly
visualize endosomal PEG shedding during NP endocytosis.
The chemical synthesis to form the FRET-bearing PEG molecule is illustrated in Scheme 1.
Specifically, Dabcyl is introduced by conjugating BOC-Lysine(COOH)-Dabcyl (1) to PEG-
hydrazide (2) using EDC/NHS coupling. After standard BOC deprotection using
trifluoroacetic acid (TFA), a disulfide bond is introduced by a heterofunctional crosslinker,
N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP), which allows for subsequent
disulfide coupling to thiol-containing molecules. The products in each conjugation step are
purified using dialysis and gel filtration. Next, we adopt solid phase synthesis to assemble a
small molecule (9) that contains a free thiol, amine and OG488 dye. Here, Fmoc-Cys(Trt)-
OH is first conjugated to Bis-(2-aminoethyl)-ether trityl resin through pyBOP/HOBt
coupling, followed by Fmoc deprotection using 20% (v/v) piperidine in DMF. Both
conjugation and deprotection reactions are confirmed by the ninhydrin test. The resin is then
reacted with amine-reactive OG488 dyes to assemble (8). Since the thiol of cystine is
protected by a trityl group, thiol deprotection and resin cleavage can thus be carried out in a
single TFA treatment. After the solvent is removed by vacuum, the molecule (9) is
immediately mixed with (4) in water to avoid potential thiol oxidation. The coupling
reaction between thiol and pyridyl disulfide results in the formation of the final FRET-
bearing PEG molecule (10). Notably, the amine group preserved in the final molecular
structure provides a functional end-group for further conjugation of FRET-bearing PEG to
different NP systems.
To confirm the conjugation reactions in scheme 1, matrix-assisted laser desorption and
ionization time-of-flight (MALDI-TOF) mass spectrometry is used to analyze key products
1, 3, 4 and 10, and plotted in Figure 2(a). The molecular weight of each product measured
from the spectra matches the predicted values (see supporting materials). UV-Vis
spectroscopy provides a simple and direct method to further confirm our MALDI-TOF
analysis. As shown in Figure 2b, the initial mPEG-hydrazide molecule (1) does not show
obvious absorption at 300 – 700 nm. After conjugation with BOC-Lysine-(COOH)-Dabcyl
(2), an absorption maximum at 460 nm was observed which matches the adsorption of the
Dabcyl molecule. Further conjugation with SPDP leads to the formation of (4), which shows
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a distinct absorption peak at 280 nm, originating from the 2-pyridyldithio group of the SPDP
molecule (see supporting materials). The final reaction between (4) and (9) forms product
(10) through the replacement of 2-pyridyldithio by the thiol group in (9). The spectrum of
(10) reveals an additional peak at 490 nm, which is consistent with the absorption
wavelength of OG488. This double-peak feature of the UV absorption spectrum confirms
FRET pair formation in the final product (10).
After the synthesis of FRET-bearing PEG (10), we conjugated this molecule with PLGA to
formulate PLGA-(FRET)-PEG NPs. PLGA-PEG NPs are well-studied polymeric drug
delivery systems, which we can now use to observe the PEG-shedding effect.[10–12] To form
PLGA-(FRET)-PEG copolymers, carboxyl-terminated PLGA (PLGA-COOH) was first
activated using EDC/NHS to form PLGA-NHS, and then conjugated to the free amine of the
FRET-bearing PEG molecule (10). By using the nanoprecipitation method as previously
reported, we formulated PLGA-(FRET)-PEG NPs with sizes that are approximately 100 –
120 nm.[10] The NP structure is depicted in Figure 3a, where the hydrophobic PLGA core is
stabilized by the surrounding hydrophilic PEG layer, and the disulfide-based FRET pair is
located at the interface of hydrophobic and hydrophilic sections.
We proceeded to examine the fluorescent emission of PLGA-(FRET)-PEG NPs in response
to a reducing stimulus. Initially, analysis by fluorescence emission spectroscopy shows a
weak absorption at 520 nm (Figure 3b). After the addition of 1 mM dithiothreitol (DTT,
disulfide cleavage reagent), the emission at 520 nm increases nearly 6-fold. This increase in
fluorescence emission at 520 nm results from disulfide cleavage which abolishes
intramolecular FRET quenching by the Dabcyl molecule. To further confirm that the
disulfide cleavage leads to PEG shedding, NP sizes were monitored after the addition of 1
mM DTT. As shown in Figure 3c, DTT rapidly induces an increase in the size of PLGA-
(FRET)-PEG NPs. In non-cleavable PLGA-PEG NP controls, a similar size increase was not
observed. This NP size increase results from particle destabilization and aggregation upon
DTT addition, confirming that disulfide cleavage leads to the loss of the stabilizing PEG
layer.[7]
To demonstrate that our molecular design makes it possible to directly measure PEG
shedding during NP interaction with target cells, we formulate folate-targeted NPs by
blending PLGA-(FRET)-PEG with 10 wt% of PLGA-PEG-folate copolymers, followed by
nanoprecipitation and self-assembly of NPs. NPs formulated using this method show
preferential targeting to the folate receptor on human nasopharyngeal epidermoid carcinoma
(KB) cells and exhibit enhanced cell uptake through receptor-mediated endocytosis (see
supporting materials).
PEG-shedding during NP endocytosis in KB cells was examined by confocal microscopy.
Images of KB cells without NP treatment were taken as background controls (Figure 4a).
After the cells were incubated with 1 mg/mL NPs for 4 hrs, green fluorescence signals can
be observed in the perinuclear region, as shown in Figure 4b. The visible green fluorescence
indicates that PEG shedding has taken place after the NP endocytosis in KB cells. As a
positive control to confirm that the fluorescence is due to endosomal disulfide cleavage and
not un-quenched OG488 emission, the cells were further treated with 100 µM DTT after NP
incubation. After DTT treatment, the fluorescent image (Figure 4c) shows similar intensity
of green fluorescence as Figure 4b, confirming that the positive readout is indeed caused by
disulfide cleavage and the consequent emission of fluorescence at 520 nm. Our microscopic
observations were confirmed by flow cytometry analyses (Figure 4d). The increase in green
fluorescence intensity in cells incubated with NPs compared to cells without NPs indicates
that disulfide cleavage and PEG shedding has taken place after NP endocytosis. Likewise,
the intensity of green fluorescence remains the same after DTT treatment.
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To simulate a non-reducing intracellular environment, KB cells were incubated with NPs in
the presence of 10 µM N-ethylmaleimide (NEM), an irreversible and membrane-permeable
thiol reagent. It has been found that NEM inhibits the ability of KB cells to cleave disulfide
bonds.[13] Therefore, NEM treatment serves as a negative control to examine endosomal
PEG shedding. Fluorescence images of cells treated with 10 µM NEM were first taken as
background controls (Figure 4e). After the addition of 1 mg/mL NPs, no fluorescence above
the background level can be measured (Figure 4f), suggesting that PEG shedding through
disulfide cleavage is completely abolished. However, the green fluorescent signal becomes
visible after the removal of NEM and the addition of 100 µM DTT (Figure 4g). Flow
cytometry analysis again confirmed this microscopic observation as shown in Figure 4h. The
spectrum of cells incubated with NPs overlaps with the background spectrum when the cells
were NEM-treated, but shifts to higher intensity if cells were subsequently incubated with
DTT. Thus, the microscopic measurements and flow cytometry analyses prove a direct
correlation of the PEG-shedding effect with fluorescence emission from NPs. Further
studies using PEG-sheddable NPs indicate that the PEG shedding largely takes place at the
early stage after endocytosis (see supporting materials). Taken together, these results imply
that FRET-bearing PEG can serve as a sensor to report the uptake and accumulation of NPs
upon PEG shedding.
Fluorescence-labeling and tracking of NP distribution in vitro and in vivo is limited by the
inability to readily differentiate intracellular vs. extracellular localization of NPs while
creating high background signals. For example, using whole-body fluorescence imaging
techniques in vivo, one may not be able to distinguish between NPs in extracellular
compartments from NPs that have been taken up by target cells. With this FRET-based PEG
technique, NPs can be observed only after intracellular PEG shedding, making it possible to
directly equate NP fluorescence with the reducing environment of intra-cellular
compartments.
In summary, herein we report to our knowledge the first direct observation of endosomal
PEG shedding during NP endocytosis by synthesizing a disulfide-based FRET-bearing PEG
molecule and applying it to a targeted PLGA-PEG NP model system. More broadly, the
sheddable PEG designed in this study is applicable to NPs where PEG functionalization is
needed, including liposomes, polymeric micelles, lipoplexes and polyplexes, and can be
tested under various conditions. Therefore, the FRET-bearing PEG molecule described here
may provide a useful tool to study the PEG shedding process and aid the design of
environmentally sensitive NP systems for improved drug delivery.
Experimental Section
Reagents and measurements
PEG reagents (mPEG-NH-NH2 and tBoc-NH-PEG-NH2) were purchased from LaysanBio
Inc. SPDP was purchased from Thermo Fisher Scientific Inc. (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (pyBOP), N-Hydroxybenzotriazole
(HOBt), and Boc-Lys(Dabcyl)-COOH were purchased from Anaspec Inc. OG488 was
purchased from Invitrogen Inc. O-Bis-(aminoethyl) ethylene glycol trityl resin was
purchased from EMD Chemicals Inc. All other chemicals including folic acid, 1-ethyl-3-[3-
dimethyl-aminopropyl] carbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS),
and N,N-diiso-propylethylamine (DIEA) were purchased from Sigma-Aldrich.
Dialysis was performed using 2K Slide-A-Lyzer® cassettes and the gel filtration was carried
out on D-Salt Dextran desalting columns, both from Thermo Fisher Scientific. In gel
filtration, the first yellow-orange band that eluted from the column was collected. MALDI-
TOF analysis was performed on an Applied Biosystems Model Voyager DE-STR instrument
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in the Biopolymer Laboratory at the Massachusetts Institute of Technology (MIT). UV-Vis
measurements were performed using a Varian Cary 100 UV-Vis spectrophotometer. The NP
size (diameter, nm) was obtained from three repeat measurements by quasi-elastic laser light
scattering with a ZetaPALS dynamic light scattering detector (15mW, λ = 676 nm;
Brookhaven Instruments Corp., Holtsville, NY).
Synthesis of (4) mPEG-(Dabcyl)-NH2
Boc-Lys(Dabcyl)-COOH (23 mg, 0.046 mmol), NHS (26 mg, 0.23 mmol) and EDC (44mg,
0.23 mmol) were dissolved in 1 mL DMF, to which 0.5 mL DMF containing 29 mg mPEG-
NHNH2 (0.0058 mmol) and 20 µL DIEA (0.11 mmol) was added. The mixture was stirred
in the dark at room temperature. After 14 hrs, the mixture was precipitated in 50 mL diethyl
ether to produce a bright red solid, followed by washing using diethyl ether. After a standard
BOC deprotection using TFA, the product was purified by dialysis and gel filtration. After
lyophilizing, the compound (4) was collected as a bright yellow powder. The conjugation
was confirmed using MALDI-TOF.
Synthesis of (5) mPEG-(Dabcyl)-OPSS
SPDP (7.8 mg, 0.025 mmol) was dissolved into DMF (0.2 mL). The solution was then
added to 25 mg mPEG-(Dabcyl)-NH2 (4, 0.005 mmol). After the solid was dissolved, 10 µL
DIEA (0.055 mmol) was added. The mixture was stirred in the dark at room temperature.
After 14 hrs, the reaction was terminated by adding 2 mL water. After dialysis and
lyophilization, the compound (5) was collected as a brown powder. The conjugation was
confirmed by MALDI-TOF.
Synthesis of (10) OG488-Cys(Trt)-ONH-CH2CH2OCH2CH2O-NH-trityl resin
Bis-(2-aminoethyl)-ether trityl resin (30 mg) was loaded into an solid phase reactor and pre-
swelled in DMF for 4 hrs at room temperature. Fmoc-Cys(Trt)-OH (94 mg, 0.16 mmol),
pyBOP (124.8 mg, 0.24 mmol) and HOBt (37 mg, 0.24 mmol) were dissolved into 0.5 mL
dry DMF and added to the resin together with DIEA (20 µL, 0.11 mmol). The reaction was
carried out in the dark for 16 hrs, followed by DMF wash and pyperidine treatment (1 mL,
20% in DMF) to deprotect the amine of the cystine. The conjugation and deprotection were
confirmed by the ninhydrin test. After washing in DMF, OG488-NHS (10mg, 0.02 mmol)
and DIEA (20 µL, 0.11 mmol) in 0.5 mL DMF was added to the resin. The mixture was
stirred in the dark for 16 hrs, followed by DCM wash. The functionalized resin was then
dried under vacuum.
Synthesis of (12) mPEG-(Dabcyl)-SS-(OG488)-NH2
30 mg functionalized resin (10) was treated with the mixture of 0.1 mL TFA, 0.4 mL DCM,
30 µL water and 10 µL triisopropylsilane for 2 hrs. The solvent was evaporated at room
temperature under vacuum. Water (2 mL) was added to the dried product to extract the
cleaved molecule. The extraction was then added to 25 mg (2). The solution was stirred in
the dark at room temperature for 12 hrs. The product (12) was purified by dialysis and gel
filtration, followed by lyophilization, and was collected as a dark brown powder. The
conjugation was confirmed by MALDI-TOF.
Synthesis of PLGA-(OG488)-SS-(Dabcyl)-mPEG
PLGA-COOH was activated to form PLGA-NHS through EDC/NHS chemistry as reported
before.[10] Briefly, 100 mg PLGA-COOH was dissolved into DCM (1mL), to which 0.5mL
DCM containing EDC (5mg, 0.027mmol) and NHS (3mg, 0.027mmol) was added. The
mixture was stirred at room temperature for 2 hrs. PLGA-NHS was then precipitated by
addition of cold methanol (50mL) and dried under vacuum. The collected polymer was
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dissolved in 1mL dry DMSO, to which 25 mg mPEG-(Dabcyl)-SS-(OG488)-NH2
(compound 12, ~0.0042 mmol) and 10 µL DIEA (0.055 mmol) was added. The mixture was
stirred in the dark for 16 hrs. The product was precipitated by the addition of 50 mL cold
methanol. As a final purification, the polymer was repeatedly dissolved in DMF followed by
precipitation in cold methanol, and finally dried in vacuum.
Nanoparticle formulation
To synthesize folate-targeted NPs by nanoprecipitation and self-assembly, PLGA-PEG-
folate (1.5 mg in 0.15 mL acetonitrile), PLGA-(FRET)-PEG (1.5 mg in 0.15 mL
acetonitrile) and acetonitrile (0.2 mL) were mixed and added dropwise into a 7 mL vial of
DI H2O under gentle stirring. The organic solvent phase was allowed to evaporate in the
dark for 16 hrs under gentle stirring. The NPs were washed with ultra pure water using 100
kDa Amicon Ultra centrifugal filters and concentrated to 0.2 mL. The NPs were transferred
into buffered solutions by a slow addition of 0.022 mL 10× PBS before the NPs were added
to cells.
Cell experiments
KB cells were purchased from ATCC and cultured in RPMI medium (RPMI-1640
containing 1 mg/L FA, Invitrogen) with 10 % fetal bovine serum, 2 mM glutamine, 50 units/
mL penicillin and 50 ug/mL streptomycin at 37 °C and 5% CO2. Cells were routinely
passaged by treatment with trypsin (0.25%) / EDTA. Before the cells were incubated with
NPs, cells were cultured overnight in FAfree RPMI medium with the same additives.
For fluorescence microscopy studies, KB cells were seeded on a 4-well chamber slide with
15,000 cells / well and incubated at 37 °C and 5% CO2 for 24 hrs. Next, the cells were
incubated in fresh complete medium with NPs, followed by a 6-hr incubation at 37 °C and
5% CO2. After the incubation, the cells were washed three times in PBS and fixed in 4%
paraformaldehyde at room temperature. For imaging, slides were mounted with a coverslip
using H-1000 Vectorshield mounting medium with DAPI. Fluorescent analysis was carried
out using an Applied Precision DeltaVision Spectris Microscope.
Flow cytometry analysis was performed on a BD Biosciences FACSCalibur HTS at the MIT
Koch Institute flow cytometry core facility. KB and HUVEC cells were seeded on 6-well
plates with a density of 200,000 cells / well and incubated overnight. To allow nanoparticle
uptake, cells were incubated with 0.5 mg / mL NPs for 4 hrs at 37 °C and 5% CO2. Before
flow cytometry analysis, cells were washed with PBS, trypsinized, and re-suspended in PBS
containing 0.4% BSA. Each flow cytometry result was collected from 12,000 live cells.
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The design of FRET-bearing PEG that allows the direct observation of its shedding.
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(a) MALDI-TOF analysis and (b) UV-Vis spectroscopy of conjugation products to form the
FRET-bearing PEG.
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(a) NP structure using PLGA-(FRET)-PEG copolymer through nanoprecipitation. (b)
Fluorescence emission spectroscopy shows that the disulfide cleavage induces a nearly 6-
fold increase in 520 nm emission compared to un-cleaved NPs. (c) The disulfide cleavage
induces PEG shedding and increase in NP size.
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Observation of endosomal PEG shedding by fluorescent microscopy and flow cytometry in:
(a)–(d) KB cells with no NEM and (e)–(h) KB cells with addition of NEM. In each row, the
fluorescent intensity at 520 nm is compared among cell-only controls, cells incubated with
NPs, and cells incubated with NPs followed by DTT treatment. In all experiments, the NP
concentration is 1 mg/mL. The DTT concentration is 100 µM and the NEM concentration is
10 µM.
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Chemical synthesis of FRET-bearing PEG.
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